Dietary Habits, Nutritional Knowledge and Physical Activity Assessment in Early Stage Breast Cancer Patients
DEMETRA
1 other identifier
observational
1,098
1 country
1
Brief Summary
The advances in early detection coupled with improvements in treatments have led to an ever increasing number of breast cancer survivors. New methods to improve outcomes, including strategies aimed at improving the quality of life and reducing the risk of other diseases, may complement the currently available treatment options. In particular, interventions targeting diet, weight and physical activity can reduce the risk of cancer occurrence, prevent cancer recurrence, and improve survival and the quality of life.This cross-sectional, prospective, observational study aims at evaluating dietary habits and nutritional knowledge in patients with early hormone receptor positive and hormone receptor negative breast cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 28, 2022
CompletedFirst Submitted
Initial submission to the registry
September 1, 2023
CompletedFirst Posted
Study publicly available on registry
October 10, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2032
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2032
October 10, 2023
October 1, 2023
9.7 years
September 1, 2023
October 5, 2023
Conditions
Outcome Measures
Primary Outcomes (3)
Evaluation of nutritional knowledge in patients with surgically removed early breast cancer
Median and interquartile range of items of nutritional knowledge questionnaire in patients with surgically removed early breast cancer
At baseline and at 3-5 years of follow up
Evaluation of dietary habits in patients with surgically removed early breast cancer
Frequency of different answers at dietary habits questionnaire
At baseline and at 3-5 years of follow up
Evaluation of physical activity in patients with surgically removed early breast cancer
Frequency of different answers at activity questionnaire
At baseline and at 3-5 years of follow up
Secondary Outcomes (9)
Association between nutritional knowledge and physical activity
At baseline and at 3-5 years of follow up
Association between nutritional knowledge and dietary habits
At baseline and at 3-5 years of follow up
Association between dietary habits and physical activity
At baseline and at 3-5 years of follow up
Association between dietary habits and BMI
At baseline and at 3-5 years of follow up
Association between dietary habits and waist to hip ratio
At baseline and at 3-5 years of follow up
- +4 more secondary outcomes
Eligibility Criteria
All patients with early stage hormone receptor positive breast cancer treated at the Department of Medical Oncology and Cancer Prevention, IRCCS National Cancer Institute of Aviano and at the other involved clinical centers considered eligible for the study will be enrolled, after providing written informed consent.
You may qualify if:
- Patients with surgically removed early stage (I-IIIa) hormone receptor-positive or hormone receptor negative breast cancer. Patients with hormone receptor-positive breast cancer can be in treatment with endocrine therapy; patients with hormone receptor-negative tumors have to be in follow-up. Concomitant use of targeted therapies with anti-hormonal agents is allowed only in adjuvant setting
- Female patients ≥18 years of age.
- Written informed consent must be obtained before any study-related assessment is performed
You may not qualify if:
- Patients with advanced/metastatic breast cancer.
- Patients with early breast cancer receiving (neo)adjuvant chemotherapy or anti-HER2 agents
- Patients receiving active treatment for secondary primary tumors (excluding basal cell carcinoma or in situ neoplasias)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
IRCCS, Centro di Riferimento Oncologico (CRO) di Aviano
Aviano, Pordonone, 33081, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mattia Garutti, MD
IRCCS-Centro di Riferimento Oncologico (CRO), Aviano (PN)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 1, 2023
First Posted
October 10, 2023
Study Start
October 28, 2022
Primary Completion (Estimated)
July 1, 2032
Study Completion (Estimated)
July 1, 2032
Last Updated
October 10, 2023
Record last verified: 2023-10